These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 7259930)

  • 1. Plasma concentrations and protein binding of disopyramide and mono-N-dealkyldisopyramide during chronic oral disopyramide therapy.
    Aitio ML
    Br J Clin Pharmacol; 1981 Apr; 11(4):369-75. PubMed ID: 7259930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous determination of disopyramide and mono-N-dealkyldisopyramide enantiomers in human plasma by capillary electrophoresis.
    Jabor VA; Lanchote VL; Bonato PL
    Electrophoresis; 2001 Apr; 22(7):1406-12. PubMed ID: 11379964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma binding of disopyramide and mono-N-dealkyldisopyramide.
    Bredesen JE; Pike E; Lunde PK
    Br J Clin Pharmacol; 1982 Nov; 14(5):673-6. PubMed ID: 7138747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein binding of disopyramide--displacement by mono-N-dealkyldisopyramide and variation with source of alpha-1-acid glycoprotein.
    Haughey DB; Steinberg I; Lee MH
    J Pharm Pharmacol; 1985 Apr; 37(4):285-8. PubMed ID: 2860235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitive high-pressure liquid chromatographic determination of disopyramide and mono-N-dealkyldisopyramide.
    Nygard G; Shelver WH; Khalil SK
    J Pharm Sci; 1979 Oct; 68(10):1318-20. PubMed ID: 512870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of silica gel with aqueous eluent for simultaneous high performance liquid chromatographic assay of disopyramide and mono-N-dealkyldisopyramide.
    Wang LH; Kushida K; Ishizaki T
    Ther Drug Monit; 1986; 8(1):85-9. PubMed ID: 3008386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetic and pharmacodynamic effects of varying the free fraction of disopyramide.
    Shaw LM; Doherty JU; Waxman HL; Josephson ME
    Angiology; 1987 Feb; 38(2 Pt 2):192-7. PubMed ID: 3826754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of serum concentrations of disopyramide and its metabolite mono-N-dealkyldisopyramide on the anticholinergic side effects associated with disopyramide.
    Tsuchishita Y; Fukumoto K; Kusumoto M; Ueno K
    Biol Pharm Bull; 2008 Jul; 31(7):1368-70. PubMed ID: 18591776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between alpha 1-acid glycoprotein and distribution of disopyramide and mono-N-dealkyldisopyramide in whole blood.
    Bredesen JE; Kierulf P
    Br J Clin Pharmacol; 1986 Sep; 22(3):281-6. PubMed ID: 3768240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of cimetidine and ranitidine on the pharmacokinetics of disopyramide in man.
    Jou MJ; Huang SC; Kiang FM; Lai MY; Chao PD
    J Pharm Pharmacol; 1997 Nov; 49(11):1072-5. PubMed ID: 9401940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between alpha 1-acid glycoprotein and plasma binding of disopyramide and mono-N-dealkyldisopyramide.
    Bredesen JE; Kierulf P
    Br J Clin Pharmacol; 1984 Nov; 18(5):779-84. PubMed ID: 6508986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous determination of disopyramide and mono-N-dealkyldisopyramide enantiomers in plasma and urine by use of a chiral cellulose-derivative column.
    Echizen H; Ochiai K; Kato Y; Chiba K; Ishizaki T
    Clin Chem; 1990 Jul; 36(7):1300-4. PubMed ID: 2372941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disopyramide concentrations in saliva.
    Aitio ML; Virtanen R; Lammintausta R
    Int J Clin Pharmacol Ther Toxicol; 1982 Feb; 20(2):68-72. PubMed ID: 7061181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding interaction between enantiomers of disopyramide and mono-N-dealkyldisopyramide on plasma protein.
    Takahashi H; Ogata H; Seki Y
    Drug Metab Dispos; 1991; 19(2):554-7. PubMed ID: 1676669
    [No Abstract]   [Full Text] [Related]  

  • 15. Enhanced metabolism and diminished efficacy of disopyramide by enzyme induction?
    Aitio ML; Vuorenmaa T
    Br J Clin Pharmacol; 1980 Feb; 9(2):149-52. PubMed ID: 7356902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High performance liquid chromatographic analysis of the antiarrhythmic drugs procainamide, disopyramide, quinidine, propranolol and metabolites from serum extracts.
    Wesley JF; Lasky FD
    Clin Biochem; 1981 Jun; 14(3):113-8. PubMed ID: 6170476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged variability in plasma protein binding of disopyramide after acute myocardial infarction.
    David BM; Ilett KF; Whitford EG; Stenhouse NS
    Br J Clin Pharmacol; 1983 Apr; 15(4):435-41. PubMed ID: 6849779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enantioselective analysis of disopyramide and mono-N-dealkyldisopyramide in plasma and urine by high-performance liquid chromatography on an amylose-derived chiral stationary phase.
    Bortocan R; Lanchote VL; Cesarino EJ; Bonato PS
    J Chromatogr B Biomed Sci Appl; 2000 Jul; 744(2):299-306. PubMed ID: 10993518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of concentration-dependent protein binding on serum concentrations and urinary excretion of disopyramide and its metabolite following oral administration.
    Haughey DB; Lima JJ
    Biopharm Drug Dispos; 1983; 4(2):103-12. PubMed ID: 6882879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A simple method for the simulation of unbound serum disopyramide concentration in patients.
    Kishino S; Kohri N; Iseki K; Miyazaki K; Nomura A; Yasuda H
    J Pharmacobiodyn; 1991 Sep; 14(9):493-9. PubMed ID: 1779403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.